-
1دورية أكاديمية
المؤلفون: Lo mauro A., Aliverti A.
المساهمون: Lo mauro, A., Aliverti, A.
مصطلحات موضوعية: Biological drugs, Neuroprotective drugs, Pharmacology, Secondary brain damage, Traumatic brain injury, Female, Humans, Lung, Male, Sex Factors, Exercise, Respiration
الوصف: Sex is a biological concept determined at conception. Gender is a social concept. Medicine recognises sex as a biological variable and recommends including sex as a factor in clinical practice norms and as a topic of bench and clinical research. Sex plays a role in respiratory physiology according to two pathways: Hormones and anatomy, with females characterised by smaller dimensions at every level of the respiratory system. Sex hormones also play specific roles in lung inflammatory processes, breathing control and in response to diseases. The literature is extremely controversial because many factors need to be considered to avoid erroneous comparisons. The main difficulty lies in creating homogeneous groups of subjects according to age, body weight, lung/airway size, fluctuations in circulating hormone levels, and exercise protocol. Because almost all of the knowledge available in physiology is based on research in males, medicine for women is therefore less evidence-based than that being applied to men. Finally, the number of transsexual people is increasing and they represent new challenges for clinicians, due to the anatomical and physiological changes that they undergo.
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/34750114; info:eu-repo/semantics/altIdentifier/wos/WOS:000769745400005; volume:30; issue:162; firstpage:1; lastpage:16; numberofpages:16; journal:EUROPEAN RESPIRATORY REVIEW; http://hdl.handle.net/11311/1206763Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85121583337
-
2
المؤلفون: Adriana L. Lopeztello-Santillán, Minerva Gómez-Flores, Lorena Estrada-Aguilar, Mario Amaya-Guerra, Mónica I. Rivera-Gómez, Gladys León-Dorantes, Delfina G. Villanueva-Quintero, Nancy Podoswa-Ozerkovsky, José Fernando Barba-Gómez, César Maldonado-García
المصدر: Gaceta Médica de México. 156
مصطلحات موضوعية: Male, medicine.medical_specialty, Tumor Necrosis Factor-alpha, business.industry, Age Factors, General Medicine, medicine.disease, Pregnancy Complications, Biological drugs, Biological Factors, Pregnancy, Psoriasis, medicine, Humans, Female, In patient, Intensive care medicine, business, Mexico, Societies, Medical
الوصف: In recent years, the introduction of a series of biological drugs for the treatment of psoriasis has considerably increased the therapeutic armamentarium of doctors, and thus a strongly positive impact on the control of this condition has been achieved. With the purpose to provide the best recommendations for the use of these biological agents in patients with psoriasis, the Mexican group of psoriasis experts, PSOMEX, has developed recommendations in order to improve the understanding and therapeutic positioning of this type of medications.En los últimos años, la introducción de diversos medicamentos biológicos para el tratamiento de la psoriasis ha aumentado considerablemente el arsenal terapéutico del médico, con lo cual se ha logrado un fuerte impacto positivo en el control de la enfermedad. Con el fin de proveer de las mejores recomendaciones para el uso de estos biológicos en los pacientes afectados de psoriasis, el grupo mexicano de expertos en psoriasis PSOMEX ha formulado recomendaciones para mejorar la comprensión y el posicionamiento terapéutico de este tipo de medicamentos.
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30f3604c65c07117a52825706157a026Test
https://doi.org/10.24875/gmm.m20000441Test -
3
المؤلفون: Sabela Fernández, Luis Cea-Calvo, Teresa Otón, María J. Arteaga, Loreto Carmona, Javier de Toro, Carlos M. González
المصدر: RUC. Repositorio da Universidade da Coruña
instnameمصطلحات موضوعية: Male, medicine.medical_specialty, Nursing (miscellaneous), Inflammatory arthritis, Decision Making, Physical Therapy, Sports Therapy and Rehabilitation, Disease, 03 medical and health sciences, 0302 clinical medicine, Rheumatology, Spondyloarthritis, Health care, medicine, Humans, Orthopedics and Sports Medicine, 030212 general & internal medicine, Rheumatoid arthritis, Medical prescription, Survey, Shared decision making, 030203 arthritis & rheumatology, Response rate (survey), Biological Products, Physician-Patient Relations, Descriptive statistics, business.industry, Arthritis, Rehabilitation, Middle Aged, medicine.disease, Preference, Subcutaneous biological drugs, Prescriptions, Family medicine, Female, Perception, Chiropractics, Patient Participation, business, Decision Making, Shared
الوصف: Short report [Abstract] Objectives: The aim of this study was to explore the preferences of patients with rheumatic diseases and their perceived experience regarding participation in shared decision making (SDM) when they were prescribed a subcutaneous (SC) biological drug. Methods: A printed survey was handed to 1,000 patients with inflammatory rheumatic diseases treated with SC biological drug. The survey included closed questions about preferences regarding decision making and about patients' experience when they were prescribed an SC biological drug. Descriptive statistics were performed with stratification by patient profiles, using chi-square for comparisons between groups. Results: A total of 592 surveys were received (response rate 59.2%, mean age 51.7 years, 57.6% women). Some 28.2% of patients reported preferring to take part in treatment selection, a percentage that was higher in younger patients, in those with higher academic degree and in those who search information in sources different to that of health care professionals. Over half of patients (56.3%) perceived that the rheumatologist considered their opinion when prescribing an SC biological drug, a percentage higher in younger people. Only in 40.8% of cases did the patients' preference match their perception of their participation in the process. No differences were observed by sex, disease or number of biologics. Conclusions: Patients with inflammatory rheumatic diseases want information about their treatments but mostly leave the prescription decision to the rheumatologist. Younger people, or those with higher academic degree, more often want to participate in the SDM. There are discrepancies between patient preferences and perceptions of this process.
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4471b697efffe0c78692c4823e97e71Test
https://doi.org/10.1002/msc.1499Test -
4
المؤلفون: Antonella LoMauro, Andrea Aliverti
المصدر: European Respiratory Review, Vol 30, Iss 162 (2021)
مصطلحات موضوعية: Pulmonary and Respiratory Medicine, Breathing control, Male, Secondary brain damage, Respiratory physiology, Diseases of the respiratory system, Traumatic brain injury, Sex Factors, Neuroprotective drugs, medicine, Humans, Biological drugs, Lung, Exercise, Pharmacology, Biological variable, RC705-779, business.industry, Respiration, Transsexual, Clinical research, medicine.anatomical_structure, Homogeneous, Female, business, Clinical psychology, Hormone
الوصف: Sex is a biological concept determined at conception. Gender is a social concept. Medicine recognises sex as a biological variable and recommends including sex as a factor in clinical practice norms and as a topic of bench and clinical research. Sex plays a role in respiratory physiology according to two pathways: hormones and anatomy, with females characterised by smaller dimensions at every level of the respiratory system. Sex hormones also play specific roles in lung inflammatory processes, breathing control and in response to diseases. The literature is extremely controversial because many factors need to be considered to avoid erroneous comparisons. The main difficulty lies in creating homogeneous groups of subjects according to age, body weight, lung/airway size, fluctuations in circulating hormone levels, and exercise protocol. Because almost all of the knowledge available in physiology is based on research in males, medicine for women is therefore less evidence-based than that being applied to men. Finally, the number of transsexual people is increasing and they represent new challenges for clinicians, due to the anatomical and physiological changes that they undergo.
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ecf4854640509c7f7f27e551e843f638Test
http://err.ersjournals.com/content/30/162/210038.fullTest -
5
المؤلفون: Francisco Maceiras, Luis Cea-Calvo, Loreto Carmona, Sagrario Bustabad, Jaime Calvo-Alén, Paloma Vela
المصدر: Reumatología Clínica (English Edition). 16:116-119
مصطلحات موضوعية: Adult, Male, medicine.medical_specialty, Adolescent, Injections, Subcutaneous, Drug Administration Schedule, Medication Adherence, Arthritis, Rheumatoid, Biological drugs, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Humans, Medicine, In patient, 030212 general & internal medicine, Aged, Retrospective Studies, Aged, 80 and over, 030203 arthritis & rheumatology, Biological Products, Motivation, business.industry, General Medicine, Middle Aged, medicine.disease, Medication possession ratio, Tolerability, Patient Satisfaction, Antirheumatic Agents, Rheumatoid arthritis, Female, business
الوصف: Objectives In the ARCO study, adherence to subcutaneous biological agents by patients with rheumatoid arthritis improved with monthly administration. We assess whether adherence can be related to fulfilment of expectations and satisfaction with treatment. Patients and methods Adherence was assessed by calculating the Medication Possession Ratio, and satisfaction and fulfilment of expectations using the EXPRESAR group questionnaire. Results In 346 patients, those who were satisfied/very satisfied with efficacy and tolerability were ≥80% and 64.4%, with no differences between weekly, biweekly or monthly administration regimens. Regarding the fulfilment of expectations, 59.9% considered the effect of the treatment greater than expected and 52.6% reported lower/much lower than expected discomfort; the latter percentage was higher in patients with monthly administration (P = .049). The percentages for nonadherence were 15.6% (discomfort greater than expected), 18.5% (expected discomfort) and 11.1% (lower than expected or no discomfort) (P = .189). Conclusions Satisfaction and fulfilment of expectations were high. Fulfilment of expectations of tolerability was better with monthly administration, which could contribute to better adherence.
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96d06a1ee131089f1171ac379e9ba1f0Test
https://doi.org/10.1016/j.reumae.2018.02.013Test -
6
المؤلفون: Dionisio Silvaggio, Colin Gerard Egan, Paul Lombardo, Marco Galluzzo, A. Massaro, Mark S. Talamonti, S D'Adamio, Luca Bianchi
المصدر: Expert Opinion on Biological Therapy. 20:95-104
مصطلحات موضوعية: Adult, Male, 0301 basic medicine, Moderate to severe, medicine.medical_specialty, Treatment response, HLA-C*06, Clinical Biochemistry, Logistic regression, Severity of Illness Index, ustekinumab, 03 medical and health sciences, 0302 clinical medicine, drug survival, Internal medicine, Psoriasis, Drug Discovery, Ustekinumab, medicine, Humans, Aged, PASI, biological drugs, Pharmacology, Plaque psoriasis, Settore MED/35 - Malattie Cutanee e Veneree, Cumulative toxicity, business.industry, Middle Aged, Retention rate, medicine.disease, Treatment Outcome, 030104 developmental biology, 030220 oncology & carcinogenesis, Female, Dermatologic Agents, business, medicine.drug
الوصف: Background: Limited information is available from real-life studies evaluating the long-term efficacy and drug retention of ustekinumab.Research design and methods: Data from 378 patients with moderate-severe psoriasis were retrospectively analyzed. Over 8 years, disease severity and treatment response were evaluated using the PASI score. Predictors of PASI response were evaluated by logistic regression. Ustekinumab retention rate was calculated by the Kaplan-Meier method.Results: Over the 8 years, >80% of patients achieved a PASI score of
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b6fca55bd86a6f9dc91db2102c3f208Test
https://doi.org/10.1080/14712598.2020.1684472Test -
7
المؤلفون: Domenico Bonamonte, Clara De Simone, Debora Lobreglio, Maurizio Congedo, Angela Filoni, Gianbattista Lobreglio, Giacomo Caldarola
المصدر: Experimental dermatologyREFERENCES. 30(7)
مصطلحات موضوعية: 0301 basic medicine, Adult, Male, medicine.medical_specialty, Adolescent, Dermatology, Biochemistry, Gastroenterology, Biological drugs, 030207 dermatology & venereal diseases, 03 medical and health sciences, Basal (phylogenetics), Young Adult, 0302 clinical medicine, Psoriasis, Internal medicine, medicine, Vitamin D and neurology, Humans, Dosing, Vitamin D, Molecular Biology, Aged, Biological Products, business.industry, Middle Aged, medicine.disease, 030104 developmental biology, Female, Total Vitamin D, business
الوصف: Data regarding the association between psoriasis and vitamin D levels are controversial [S1-S2] , maybe due to the choice of dosing serum total 25(OH)D in order to assess the vitamin D nutritional state both at its basal levels and after supplementation [S3-S4] .
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::456cf2609213c3d35a546da3bcd2171cTest
https://pubmed.ncbi.nlm.nih.gov/33687755Test -
8
المؤلفون: Alessia Ruibal Pereira, María Teresa Abalde, Virginia Fernández-Redondo, Queila Rodríguez-Jato, Crisitina Martinez-Reglero, Laura Salgado-Boquete, Ángeles Flórez, Ana Batalla
المصدر: Journal of drugs in dermatology : JDD. 20(2)
مصطلحات موضوعية: Adult, Male, medicine.medical_specialty, MEDLINE, Disease, Severity of Illness Index, Biological drugs, Psoriasis, Extensive data, Medicine, Humans, In patient, Aged, Retrospective Studies, Biological therapies, Biological Products, business.industry, General Medicine, Middle Aged, medicine.disease, Hospitalization, Cross-Sectional Studies, Emergency medicine, Population study, Regression Analysis, Female, business
الوصف: Background Psoriasis is an immunomediated disease mostly controlled at the outpatient level, although there is a low percentage of patients that require systemic drugs or even hospitalization for an adequate control. Biological drugs have represented a turning point in its treatment. So far, despite the growing interest in psoriasis and its management with biological therapies, there is a lack of studies focusing on their impact on hospitalization, a relevant issue to patients and to the sustainability of our healthcare system. Objective In this study, we aimed to describe the temporal evolution of the hospitalizations of patients with psoriasis throughout the period between eight years before the commercialization of the first biological drugs and present, and secondly, whether this market irruption was related to a decrease in the number of admissions. Methods Data was collected retrospectively from the Dermatology department of the Complexo Hospitalario Universitario de Ponte- vedra (CHUP) including patients of all ages with a diagnosis of psoriasis and at least one admission to the department of Dermatology along the study period. We established different time periods for comparing the average hospitalizations per 100,000 inhabitants-year and the average stay, considering that the first biologic drug marketed for the treatment of psoriasis was in 2004. Results Regression models indicated a significant change in the temporal trend of the hospitalization rate per 100,000 inhabitants-year starting in 2004. In all cases, a gradual and significant decrease in the number of admissions per 100,000 inhabitants-year and in the average hospitalization rate per psoriasis per 100,000 inhabitants-year along the study period were found. There was also a significant decrease in medical hospitalizations and medical hospitalizations excluding psoriasis throughout the study period. Conclusions In our study population hospitalizations for psoriasis descended progressively and significantly from 2004. So far there are no extensive data on the impact of biological therapies on psoriasis hospitalization. J Drugs Dermatol. 2021;20(2):208-214. doi:10.36849/JDD.4931.
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28fb4b5d1623bd1f7cada176bceee7e4Test
https://pubmed.ncbi.nlm.nih.gov/33538560Test -
9
المؤلفون: S. Pagani, Claudio Santoro, Mathieu Ferrari, Pedro L Alves, Daniele Sblattero, Alessandra Nerviani, Cecilia Deantonio, Federico Colombo, Shimobi Onuoha, Liliane Fossati-Jimack, Costantino Pitzalis
المساهمون: Ferrari, Mathieu, Onuoha, Shimobi C, Fossati-Jimack, Liliane, Nerviani, Alessandra, Alves, Pedro L, Pagani, Sara, Deantonio, Cecilia, Colombo, Federico, Santoro, Claudio, Sblattero, Daniele, Pitzalis, Costantino
المصدر: Frontiers in Immunology, Vol 12 (2021)
Frontiers in Immunologyمصطلحات موضوعية: 0301 basic medicine, Male, rheumatoid arthritis, biological drug, Mice, SCID, Immunoglobulin G, Arthritis, Rheumatoid, Mice, 0302 clinical medicine, Rheumatoid, Antibodies, Bispecific, Medicine, Immunology and Allergy, Single-Chain Antibodie, anti-TNF therapy, biological drugs, bispecific antibody, targeted therapy, Adalimumab, Animals, Disease Models, Animal, Female, Humans, Immunotherapy, Inflammation, Single-Chain Antibodies, Synovial Membrane, Tumor Necrosis Factor Inhibitors, Tumor Necrosis Factor-alpha, Original Research, Tumor Necrosis Factor Inhibitor, biology, Rheumatoid arthritis, Drug delivery, Systemic administration, Tumor necrosis factor alpha, Bispecific, Antibody, medicine.drug, Human, musculoskeletal diseases, lcsh:Immunologic diseases. Allergy, Immunology, SCID, Antibodies, 03 medical and health sciences, Immune system, 030203 arthritis & rheumatology, business.industry, Animal, Arthritis, rheumatoid arthriti, medicine.disease, 030104 developmental biology, Disease Models, biology.protein, business, lcsh:RC581-607
الوصف: Biologic drugs, especially anti-TNF, are considered as the gold standard therapy in rheumatoid arthritis. However, non-uniform efficacy, incidence of infections, and high costs are major concerns. Novel tissue-specific agents may overcome the current limitations of systemic administration, providing improved potency, and safety. We developed a bispecific antibody (BsAb), combining human arthritic joint targeting, via the synovial-specific single-chain variable fragment (scFv)-A7 antibody, and TNFα neutralization, via the scFv-anti-TNFα of adalimumab, with the binding/blocking capacity comparable to adalimumab -immunoglobulin G (IgG). Tissue-targeting capacity of the BsAb was confirmed on the human arthritic synovium in vitro and in a synovium xenograft Severe combined immune deficient (SCID) mouse model. Peak graft accumulation occurred at 48 h after injection with sustained levels over adalimumab-IgG for 7 days and increased therapeutic effect, efficiently decreasing tissue cellularity, and markers of inflammation with higher potency compared to the standard treatment. This study provides the first description of a BsAb capable of drug delivery, specifically to the disease tissue, and a strong evidence of improved therapeutic effect on the human arthritic synovium, with applications to other existing biologics.
وصف الملف: ELETTRONICO
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e61b9a28fd487da2e9f013f6f47b2da7Test
https://www.frontiersin.org/articles/10.3389/fimmu.2021.640070/fullTest -
10
المؤلفون: Masaaki Kusumoto, Yoshitaka Yano, Nobuhiko Nakamura
المصدر: The International journal of pharmacy practice. 29(4)
مصطلحات موضوعية: Male, Pharmaceutical Science, Antineoplastic Agents, Pharmacy, Demographic data, Vial, Infliximab Injection, Cost burden, Biological drugs, Toxicology, 03 medical and health sciences, 0302 clinical medicine, Japan, Medicine, Humans, 030212 general & internal medicine, Average cost, Demography, National health, business.industry, 030503 health policy & services, Health Policy, Public Health, Environmental and Occupational Health, Infliximab, Christian ministry, Female, 0305 other medical science, business
الوصف: Objectives Drug wastage costs in the medical field must be reduced, particularly for expensive biological drugs. In Japan, the Ministry of Health, Labour and Welfare (MHLW) has developed specific criteria for the divided use of injectable vials and vial sharing of anticancer injection drugs to reduce drug wastage. This study investigates the optimal vial size for infliximab infusion to reduce drug wastage in Japan. Method A log-normal distribution was assumed for body weight, and hypothetical data were simulated using the software R. We assumed the average wastage in milligrams (mg) by considering different vial sizes in addition to the existing 100 mg size. We also assumed 18 different vial size combinations for rheumatism patients by gender. The range was 10–95 mg with 5 mg increments. Using the total amount of wasted doses for the existing 100 mg size as a baseline, we evaluated the effect of using additional vial sizes on the total amount of wasted doses. Key findings The average cost of infliximab wastage per case was found to be US$ 353.8 for males and US$ 359.6 for females. For a 15 mg plus 100 mg combination, the average cost of infliximab wastage per case became US$ 20.2 for males and US$ 26.1 for females. In other words, infliximab wastage would be reduced by 94.3% for males and 92.8% for females. Conclusions Adding a 15 mg vial size to the existing 100 mg size can reduce wastage. Producing drugs in different vial sizes can thus help significantly reduce the cost burden on the national health care system.
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5f45104de3fb1342301d5c725034034Test
https://pubmed.ncbi.nlm.nih.gov/33881507Test
